Helius Medical Technologies - Home


Call us: +1 877-564-0008


Stock Quote - HSDT

*Delayed quote courtesy of Google.

(Newtown, PA) – June 15, 2016 – Helius Medical Technologies, Inc. (TSX: HSM; OTCQB: HSDT) (“Helius”, or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, today opened the market of the Toronto Stock Exchange in celebration of becoming a member of the TSX. The company began trading on the TSX on April 18, 2016.

“Listing on the TSX, the premier exchange in Canada, marks an important step in the growth and evolution of Helius Medical Technologies. We believe that trading on the TSX will provide greater access to capital in order to continue forth with our key objective to drive ongoing clinical trials and development of the Company’s PoNS device,” said CEO Phil Deschamps.

Video of the event can be found here.

About the PoNS™

The Portable Neuromodulation Stimulator (PoNS) device is an investigational medical device being studied for the treatment of neurological symptoms caused by disease or trauma. The PoNS is currently being studied in the United States and Canada for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury (mTBI), and in Canada for the treatment of gait and balance disorder for subjects with Multiple Sclerosis (MS).

The PoNS device is a non-invasive means for delivering neurostimulation through the tongue. Researchers believe that use of the tongue as a gateway to the brain may be one of the most natural, non-invasive and direct ways to stimulate the brain. The tongue is anatomically unique, being richly innervated by thousands of nerve fibers and interconnected to the brainstem by two major cranial nerves.

About Helius Medical Technologies (HMT)

Helius Medical Technologies is a medical technology company focused on neurological wellness. HMT seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com. The contents of this website are not, and should not be deemed to be, incorporated by reference herein.

# # #


Corporate Contact:
Phil Deschamps

Investor Relations:

Media Contact:
Becky Kern